Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Equivalence of ELISpot assays demonstrated between major HIV network laboratories.

Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, Kopycinski J, Hayes P, Hahn B, Birungi J, Tarragona-Fiol T, Wan H, Randles M, Cooper AR, Ssemaganda A, Clark L, Kaleebu P, Self SG, Koup R, Wood B, McElrath MJ, Cox JH, Hural J, Gilmour J.

PLoS One. 2010 Dec 14;5(12):e14330. doi: 10.1371/journal.pone.0014330.

PMID:
21179404
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.

Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, Birungi J, Kitandwe P, Semaganda A, Kaleebu P, Stevens G, Anzala O, Farah B, Ogola S, Indangasi J, Mhlanga P, Van Eeden M, Thakar M, Pujari A, Mishra S, Goonetilleke N, Moore S, Mahmoud A, Sathyamoorthy P, Mahalingam J, Narayanan PR, Ramanathan VD, Cox JH, Dally L, Gill DK, Gilmour J.

Clin Vaccine Immunol. 2009 Feb;16(2):147-55. doi: 10.1128/CVI.00326-08. Epub 2008 Dec 17.

PMID:
19091991
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials.

Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D'souza MP; Elispot Collaborative Study Group.

AIDS Res Hum Retroviruses. 2005 Jan;21(1):68-81.

PMID:
15665646
[PubMed - indexed for MEDLINE]
4.

Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay.

Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, Anderson K, Collins KB, Gaunt C, Fernandez VR, Zhu L, Kierstead L, Thaler S, Gupta SB, Straus W, Mehrotra D, Tobery TW, Casimiro DR, Shiver JW.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):20-7.

PMID:
17310936
[PubMed - indexed for MEDLINE]
5.

Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.

Mwau M, McMichael AJ, Hanke T.

AIDS Res Hum Retroviruses. 2002 Jun 10;18(9):611-8.

PMID:
12079556
[PubMed - indexed for MEDLINE]
6.

Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay.

Samri A, Durier C, Urrutia A, Sanchez I, Gahery-Segard H, Imbart S, Sinet M, Tartour E, Aboulker JP, Autran B, Venet A; ANRS ELISpot Standardization Group.

Clin Vaccine Immunol. 2006 Jun;13(6):684-97.

PMID:
16760328
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.

Moodie Z, Huang Y, Gu L, Hural J, Self SG.

J Immunol Methods. 2006 Aug 31;315(1-2):121-32. Epub 2006 Aug 15.

PMID:
16959262
[PubMed - indexed for MEDLINE]
8.

Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC.

Kierstead LS, Dubey S, Meyer B, Tobery TW, Mogg R, Fernandez VR, Long R, Guan L, Gaunt C, Collins K, Sykes KJ, Mehrotra DV, Chirmule N, Shiver JW, Casimiro DR.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):86-92.

PMID:
17263637
[PubMed - indexed for MEDLINE]
9.

ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring--even in hands of ELISPOT-inexperienced investigators.

Zhang W, Caspell R, Karulin AY, Ahmad M, Haicheur N, Abdelsalam A, Johannesen K, Vignard V, Dudzik P, Georgakopoulou K, Mihaylova A, Silina K, Aptsiauri N, Adams V, Lehmann PV, McArdle S.

J Immunotoxicol. 2009 Dec;6(4):227-34. doi: 10.3109/15476910903317546.

PMID:
19908941
[PubMed - indexed for MEDLINE]
10.

Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.

Shafer-Weaver K, Rosenberg S, Strobl S, Gregory Alvord W, Baseler M, Malyguine A.

J Immunother. 2006 May-Jun;29(3):328-35.

PMID:
16699376
[PubMed - indexed for MEDLINE]
11.

Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials.

Hudgens MG, Self SG, Chiu YL, Russell ND, Horton H, McElrath MJ.

J Immunol Methods. 2004 May;288(1-2):19-34.

PMID:
15183082
[PubMed - indexed for MEDLINE]
12.

The role of IFN-gamma Elispot assay in HIV vaccine research.

Streeck H, Frahm N, Walker BD.

Nat Protoc. 2009;4(4):461-9. doi: 10.1038/nprot.2009.7.

PMID:
19282851
[PubMed - indexed for MEDLINE]
13.

Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.

Sambor A, Garcia A, Berrong M, Pickeral J, Brown S, Rountree W, Sanchez A, Pollara J, Frahm N, Keinonen S, Kijak GH, Roederer M, Levine G, D'Souza MP, Jaimes M, Koup R, Denny T, Cox J, Ferrari G.

J Immunol Methods. 2014 Jul;409:107-16. doi: 10.1016/j.jim.2014.04.005. Epub 2014 Apr 29.

PMID:
24787274
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.

Ozaki DA, Gao H, Todd CA, Greene KM, Montefiori DC, Sarzotti-Kelsoe M.

PLoS One. 2012;7(1):e30963. doi: 10.1371/journal.pone.0030963. Epub 2012 Jan 27.

PMID:
22303476
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).

Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A; Elispot Proficiency Panel of the CVC Immune Assay Working Group.

Cancer Immunol Immunother. 2008 Mar;57(3):303-15. Epub 2007 Aug 25.

PMID:
17721781
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.

Kutscher S, Dembek CJ, Allgayer S, Heltai S, Stadlbauer B, Biswas P, Nozza S, Tambussi G, Bogner JR, Stellbrink HJ, Goebel FD, Lusso P, Tinelli M, Poli G, Erfle V, Pohla H, Malnati M, Cosma A.

AIDS Res Ther. 2008 Oct 6;5:22. doi: 10.1186/1742-6405-5-22.

PMID:
18837993
[PubMed]
Free PMC Article
17.

A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.

Eller MA, Slike BM, Cox JH, Lesho E, Wang Z, Currier JR, Darden JM, Polonis VR, Vahey MT, Peel S, Robb ML, Michael NL, Marovich MA.

PLoS One. 2011;6(9):e24254. doi: 10.1371/journal.pone.0024254. Epub 2011 Sep 16.

PMID:
21949699
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Statistical evaluation of HIV vaccines in early clinical trials.

Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND.

Contemp Clin Trials. 2006 Apr;27(2):147-60. Epub 2006 Jan 19.

PMID:
16426900
[PubMed - indexed for MEDLINE]
19.

The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.

Sanchez AM, Rountree W, Berrong M, Garcia A, Schuetz A, Cox J, Frahm N, Manak M, Sarzotti-Kelsoe M, D'Souza MP, Denny T, Ferrari G.

J Immunol Methods. 2014 Jul;409:31-43. doi: 10.1016/j.jim.2014.03.017. Epub 2014 Mar 28.

PMID:
24685833
[PubMed - indexed for MEDLINE]
20.

Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies.

Sanchez AM, Denny TN, O'Gorman M.

J Immunol Methods. 2014 Jul;409:1-5. doi: 10.1016/j.jim.2014.05.016. Epub 2014 Jun 6.

PMID:
24910413
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk